200 related articles for article (PubMed ID: 25424586)
1. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques.
Murphy CT; Heller S; Ruth K; Buyyounouski MK; Weinberg D; Uzzo RG; Plimack E; Kutikov A; Chen DYT; Horwitz EM
Pract Radiat Oncol; 2015; 5(3):e215-e222. PubMed ID: 25424586
[TBL] [Abstract][Full Text] [Related]
2. Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy.
White EC; Murphy JD; Chang DT; Koong AC
Am J Clin Oncol; 2015 Dec; 38(6):564-9. PubMed ID: 24401668
[TBL] [Abstract][Full Text] [Related]
3. Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review.
Trotta M; Patel KR; Singh S; Verma V; Ryckman J
Pract Radiat Oncol; 2023; 13(5):454-465. PubMed ID: 37100389
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.
Lischalk JW; Blacksburg S; Mendez C; Repka M; Sanchez A; Carpenter T; Witten M; Garbus JE; Evans A; Collins SP; Katz A; Haas J
Radiat Oncol; 2021 Jul; 16(1):126. PubMed ID: 34243797
[TBL] [Abstract][Full Text] [Related]
5. Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease.
Mohammed W; Hoskin P; Henry A; Gomez-Iturriaga A; Robinson A; Nikapota A
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):534-538. PubMed ID: 30099986
[TBL] [Abstract][Full Text] [Related]
6. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
[TBL] [Abstract][Full Text] [Related]
7. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
[TBL] [Abstract][Full Text] [Related]
8. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
[TBL] [Abstract][Full Text] [Related]
10. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
11. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
Shimizuguchi T; Nihei K; Okano T; Machitori Y; Ito K; Karasawa K
Int J Clin Oncol; 2017 Apr; 22(2):373-379. PubMed ID: 27778117
[TBL] [Abstract][Full Text] [Related]
12. Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.
Sasaki N; Yamazaki H; Shimizu D; Suzuki G; Masui K; Nakamura S; Okabe H; Nishikawa T; Yoshida K
Anticancer Res; 2018 Jan; 38(1):385-391. PubMed ID: 29277799
[TBL] [Abstract][Full Text] [Related]
13. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
14. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease.
Pai HH; Keyes M; Morris WJ; Christie J
Brachytherapy; 2013; 12(2):126-33. PubMed ID: 22738665
[TBL] [Abstract][Full Text] [Related]
15. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease.
Song DY; Lawrie WT; Abrams RA; Kafonek DR; Bayless TM; Welsh JS; DeWeese TL
Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):455-9. PubMed ID: 11567821
[TBL] [Abstract][Full Text] [Related]
16. Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series.
Juarez JE; Romero T; Mantz CA; Pepin A; Aghdam N; Suy S; Steinberg ML; Levin-Epstein RG; Nickols NG; Kaplan ID; Meier RM; Pham HT; Linson PW; Hong RL; Buyyounouski MK; Bagshaw HP; Fuller DB; Katz AJ; Loblaw A; Collins SP; Kishan AU
Adv Radiat Oncol; 2021; 6(6):100759. PubMed ID: 34585025
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
18. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
[TBL] [Abstract][Full Text] [Related]
19. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
Büchser D; Casquero F; Espinosa JM; Perez F; Minguez P; Martinez-Indart L; Suarez F; Gonzalez A; Cacicedo J; San Miguel I; Maleta A; Gomez-Caamaño A; Bilbao P; Gomez-Iturriaga A
Radiother Oncol; 2019 Jun; 135():13-18. PubMed ID: 31015158
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer.
Löser A; Beyer B; Carl CO; Löser B; Nagaraj Y; Frenzel T; Petersen C; Krüll A; Graefen M; Schwarz R
Strahlenther Onkol; 2019 May; 195(5):374-382. PubMed ID: 30390115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
